Newsroom | 11999 results

SCHAUMBURG, Ill.--(BUSINESS WIRE)--MDDAP is empowering professionals with new opportunities to excel in the medical device sector through a cutting-edge learning pathway designed for the Voluntary Improvement Program (VIP). This initiative provides essential certifications leveraging the Medical Device Discovery Appraisal Program (MDDAP), equipping appraisers to grow in their careers, access new revenue opportunities, and contribute to continuous improvement efforts within the industry. MDDAP i...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock, payable June 13, 2025, to holders of the Common Stock of record at the close of business on May 9, 2025. The second-quarter 2025 cash dividend will be the 346th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring t...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor for clinical evaluation. The Company expects to initiate a Phase 1/2a study in mid-2025 with plans for multiple expansion cohorts, including combinations, i...

DUBLIN--(BUSINESS WIRE)--The "Dairy Blends Market - Focused Insights 2025-2030" report has been added to ResearchAndMarkets.com's offering. The Dairy Blends Market was valued at USD 2.73 billion in 2024, and is projected to reach USD 3.44 billion by 2030, rising at a CAGR of 3.93%. The global dairy blends market report consists of exclusive data on 24 vendors. The market is highly competitive, with key players such as Fonterra Co-operative Group, Arla Foods, Lactalis, Agropur, FrieslandCampina,...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology (ASC...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced two presentations, including an oral presentation on the Phase 1/2 Agni-01 multicenter study of OBX-115, a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), in patients with immune checkpoint inhi...

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI to file for Regulatory Approval of Multikine in Saudi Arabia—Pursuing local partnerships to serve Middle East and North Africa Market...

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, today announced that as part of its ongoing efforts to broaden access to the CVAC System, the Company will leverage the upcoming AUA2025 annual meeting to showcase new clinical data and share learnings with the urology community. The Company’s presence at AUA2025 includes at least eight abstracts and a variety of additional educational opportunities that w...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable precision radiopharmaceuticals for cancer, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, being held from April 25 – 30, 2025 in Chicago, IL. These include: (1) a poster presentation of Abdera’s ongoing Phase 1 clinical trial...

BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Results...